Related Experiment Video
Updated: May 26, 2026

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Primary diffuse large B-cell lymphoma in the era of targeted therapies: incidence, second primary malignancy and
Jing Wang1,2, Dongming Zhou1, Chenglan Lv1
1Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, PR China.
Background:
To comprehensively illustrate the status of primary diffuse large B-cell lymphoma (DLBCL) in the era of targeted therapies.
Research Design And Methods:
Data from patients who were newly diagnosed with primary DLBCL from 2000 to 2021 in SEER 17 Registry Database were analyzed. The incidence and occurrence of second primary malignancies (SPM) and the prognosis of DLBCL were identified.
Results:
A total of 106,501 DLBCL patients were included. The median age at diagnosis was 66.0 years, and the disease was more prevalent in male and white patients. The age-standardized incidence rate in 2021 was 5.6 per 100,000, showing a significant decrease (average annual percent change of -0.43%) from 2002 to 2021. The risk of developing any SPM among DLBCL survivors was approximately 30% higher than that in the general population (95% confidence interval (CI): 1.28-1.33, p < 0.05). Significant risk factors for SPMs included the male sex (hazard ratio (HR) = 1.21, 95% CI: 1.16-1.27) and a diagnosis after 2009 (HR = 1.25, 95% CI: 1.20-1.31).
Conclusions:
The incidence of DLBCL has slightly decreased, whereas the risk of SPM has increased. The prognosis has improved, likely because of targeted therapies. Further investigation is warranted to refine treatment strategies and reduce the SPM risk.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Abnormal Proliferation